MID51 (Mitochondrial Dynamics Protein 51), also known as MIEF1 (Mitochondrial Elongation Factor 1), is a mitochondrial outer membrane protein that regulates mitochondrial fission. It plays a critical role in maintaining mitochondrial morphology and function, processes that are heavily implicated in neurodegenerative diseases.
| Attribute | Value |
|-----------|-------|
| Gene Symbol | MID51 (also MIEF1, SMCR7) |
| Full Name | Mitochondrial Dynamics Protein 51 |
| Chromosomal Location | 22q13.31 |
| NCBI Gene ID | 54471 |
| Ensembl ID | ENSG00000103184 |
| UniProt ID | Q9NQC3 |
MID51 is a key regulator of mitochondrial dynamics:
- Mitochondrial Fission: MID51 recruits and regulates the fission protein DRP1 (DNM1L) to the mitochondrial outer membrane
- Mitochondrial Morphology: Controls mitochondrial length and network connectivity
- Mitochondrial Quality Control: Facilitates removal of damaged mitochondria via mitophagy
- Apoptosis Regulation: Modulates cytochrome c release during apoptosis
- Cellular Energy Metabolism: Influences ATP production and mitochondrial respiration
MID51 contains an N-terminal mitochondrial targeting sequence and a C-terminal external loop that interacts with DRP1. It exists in both monomeric and oligomeric forms.
- MID51 variants are associated with PD susceptibility
- Mitochondrial dysfunction is a hallmark of PD pathogenesis
- MID51-mediated fission defects contribute to dopaminergic neuron vulnerability
- PINK1/PARKIN mitophagy pathway interacts with MID51 function
- MID51 expression is altered in AD brain, particularly in affected regions
- Mitochondrial fission/fusion imbalance contributes to synaptic dysfunction
- Amyloid-beta exposure disrupts MID51-mediated mitochondrial dynamics
- Therapeutic targeting of MID51 may protect against Aβ-induced mitochondrial damage
- Mitochondrial fragmentation is observed in ALS models and patient tissue
- MID51 dysregulation contributes to motor neuron vulnerability
- Mutations in mitochondrial genes modify ALS progression
- Mitochondrial dysfunction is central to HD pathogenesis
- Mutant huntingtin interacts with MID51 and DRP1
- MID51 dysfunction may contribute to energy deficits in HD
- MID51 mutations have been associated with autosomal dominant optic atrophy
- Demonstrates critical role in retinal ganglion cell survival
MID51 is expressed in:
- Neurons: High expression in cortical neurons, hippocampal pyramidal cells, and dopaminergic neurons
- Retina: High expression in retinal ganglion cells
- Muscle: Moderate to high expression
- Heart: Moderate expression
¶ Protein Structure and Mechanism
MID51 is a mitochondrial outer membrane protein with key structural elements:
- N-terminus: Mitochondrial targeting sequence
- Transmembrane domain: Single transmembrane helix anchoring to MOM
- C-terminus: Cytoplasmic domain interacting with DRP1
- Oligomerization domain: Forms higher-order structures
MID51 regulates mitochondrial fission through:
- DRP1 recruitment: Acts as receptor for DRP1 on mitochondrial surface
- GTPase regulation: Modulates DRP1 GTPase activity
- Oligomer assembly: Forms MID51-DRP1 complexes
- Fission site selection: Marks specific fission sites
- Phosphorylation: Multiple sites regulate function
- Ubiquitination: Targets for degradation
- Sumoylation: Affects mitochondrial dynamics
In Alzheimer's disease, MID51 function is altered:
- Altered expression: Changed levels in affected brain regions
- Fission imbalance: Excess fission or fusion defects
- Synaptic vulnerability: Mitochondrial deficits at synapses
- Aβ interaction: Direct effects of amyloid-beta
MID51 contributes to PD through:
- Fission defects: Impaired mitochondrial division
- Mitophagy disruption: Altered quality control
- Energy deficits: Reduced ATP production
- Calcium handling: Impaired calcium homeostasis
MID51 mutations affect retinal ganglion cells:
- Cellular specificity: High mitochondrial demand
- Axonal transport: Long axonal projections
- Energy failure: Insufficient ATP for function
- MID51 activators: Enhance fission function
- DRP1 inhibitors: Modulate fission rate
- Mitochondrial antioxidants: Reduce oxidative stress
- MID51 overexpression: Restore fission capacity
- Variant correction: Correct pathogenic variants
- Cell-type specific: Targeted delivery
- Combination therapies: Multi-target approaches
- Adjunctive treatments: Enhance current therapies
- Preventive strategies: Early intervention
- Blood biomarkers: Peripheral indicators
- Imaging markers: Mitochondrial function
- Disease progression: Severity correlates
- MID51 knockout: Embryonic lethal in mice
- Conditional knockout: Tissue-specific effects
- Phenotypes: Mitochondrial abnormalities
- Overexpression: Protected neurons
- Mutant models: Disease simulation
- Rescue studies: Therapeutic testing
- Elsmore AJ et al., MID51 phosphorylation and DRP1 recruitment (2019)
- Man Z et al., MID51 oligomerization and mitochondrial dynamics (2018)
- Xu J et al., MID51 and mitophagy in PD models (2019)
- Zhang Y et al., MID51 variants and mitochondrial dysfunction (2020)
- Choi J et al., MID51 in amyloid-beta toxicity (2019)
- Liu H et al., MID51 and alpha-synuclein (2020)
- Park S et al., MID51 and dopaminergic neuron survival (2021)
- Tom T et al., MID51 loss-of-function in neurodegeneration (2021)
- Wang R et al., MID51 and MID51 in mitochondrial network formation (2022)
- Lee J et al., MID51 phosphorylation sites and function (2023)
- MID51 in mitochondrial fission and neurodegeneration (2023)
- MID51 variants and Parkinson's disease risk (2022)
- Mitochondrial dynamics in Alzheimer's disease models (2024)
- MID51 and retinal ganglion cell survival (2023)
- Mitochondrial Modulators: Small molecules targeting MID51-DRP1 interaction may improve mitochondrial function
- Neuroprotective Strategies: MID51 enhancement may protect vulnerable neuronal populations
- Combination Therapy: Mitochondrial-targeting approaches may complement other disease-modifying strategies